Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ilomedin (iloprost) safety after PCI
2010-019920-30Phase 2Completed
- Sponsor
- Rigshospitalet,Cardiology Laboratory 2013
- Start
- Jun 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in myocardial infarction (MI), Acute cardiac ischemia (ACI) and coronary arteriosclerosis comparing Ilomedin arm with Placebo arm (2 arms). Primary endpoints: Bleeding complications during Ilomedin infusion and Hypotension during Ilomedin infusion. Started Jun 2010; status: completed.
02
Drugs
iloprost
03
Conditions
myocardial infarction (MI)Acute cardiac ischemia (ACI)coronary arteriosclerosis
Beyond the preview
Go deeper on 2010-019920-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019920-30.